Prevention of end-stage renal disease (ESRD) by early detection and treatment is an
important tool to stop the growing need for renal replacement therapy. The last decade has …

Different biochemical markers exist in both blood and urine for assessing renal function.
Most of these biomarkers have advantages and limitations associated with their use, which …

The prevalence of renal diseases is rising and reaching 5–15% of the adult population.
Renal damage is associated with disturbances of body homeostasis and the loss of …

Diabetic nephropathy (DN) is a serious complication of diabetes caused by changes in the
structure and function of the kidneys. It is important to detect diagnostic biomarkers of DN at …

Numerous clinical trials are currently evaluating new strategies to halt the progression of
renal damage in patients with chronic kidney diseases (CKDs). Unfortunately, none of them …

Chronic kidney disease (CKD) is a progressive condition characterized by a permanent and
irreversible loss of renal function. In accordance to international guidelines, CKD clinical …

The identification of the phospholipase A2 receptor 1 (PLA2R) and thrombospondin type-1
domain-containing protein 7A (THSD7A) as podocyte antigens in adult patients with …

Patients with chronic kidney disease (CKD) are, compared to the general population, at
higher risk of cardiovascular disease (CVD), including sudden death, coronary artery …

For over 70 years, serum creatinine has remained the primary index for detection and
monitoring of kidney disease. Tubulointerstitial damage and fibrosis are highly prognostic for …

Chronic kidney disease (CKD) remains a major challenge in nephrology and for public
health care, affecting 14% to 15% of the adult US population and consuming significant …